Anhui Anke Biotechnology (Group) Co., Ltd. (SHE:300009)
7.63
-0.07 (-0.91%)
Nov 17, 2026, 3:04 PM CST
SHE:300009 Revenue
Anhui Anke Biotechnology (Group) had revenue of 554.34M CNY in the quarter ending September 30, 2026, a decrease of -17.31%. This brings the company's total for the last twelve months to 2.34B, down -9.36% year-over-year. In the year 2025, Anhui Anke Biotechnology (Group) had annual revenue of 2.65B with 4.36% growth. That makes Anhui Anke Biotechnology (Group) the 13,470th largest company in the world by revenue and 2,385th in China.
Revenue (ttm)
2.34B
Revenue Growth
-9.36%
P/S Ratio
5.49
Revenue / Employee
932.60K
Employees
2,505
Market Cap
12.72B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full SHE:300009 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.65B | 110.48M | 4.36% |
| Dec 31, 2024 | 2.54B | -329.71M | -11.51% |
| Dec 31, 2023 | 2.87B | 534.69M | 22.94% |
| Jan 1, 2023 | 2.33B | 162.30M | 7.48% |
| Dec 31, 2021 | 2.17B | 467.35M | 27.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tibet Cheezheng Tibetan Medicine | 2.23B |
| Inner Mongolia Furui Medical Science | 1.64B |
| Jinyu Bio-technology | 1.60B |
| Nanjing Vazyme Biotech | 1.56B |
| BrightGene Bio-Medical Technology | 1.34B |
| Sinocelltech Group | 1.14B |
| Acrobiosystems | 1.03B |
| GemPharmatech | 941.80M |